Risk factors for treatment failures in antineutrophil cytoplasmic antibody- associated small-vessel vasculitis.
In the past several years, significant progress has occurred in the therapeutic management of antineutrophil cytoplasmic antibody-associated vasculitis. This has resulted in improved survival rates for all members of this group of inflammatory vascular disorders. However, the rate of treatment failure or resistance and relapse has remained relatively constant despite therapeutic advances. This article reviews risk factors associated with these failures, with hopes that better understanding may lead to improved therapeutic responses and less therapy-related toxicity.
Karia
Vijay R
VR
Department of Internal Medicine, Section of Rheumatology, Louisiana State University Health Sciences Center at New Orleans, 1542 Tulane Avenue, New Orleans, LA 70112, USA.
Espinoza
Luis R
LR
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D019268:Antibodies, Antineutrophil Cytoplasmic / Q000276:immunology; D003520:Cyclophosphamide / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D012307:Risk Factors; D017211:Treatment Failure; D014657:Vasculitis / Q000188:drug therapy* / Q000276:immunology
D000276:Adjuvants, Immunologic; D019268:Antibodies, Antineutrophil Cytoplasmic; D005938:Glucocorticoids; D003520:Cyclophosphamide